Researchers at National Taiwan University Hospital in Taiwan suggest physicians and patients should use caution when prescribing or taking the medications, known as nonsteroidal anti-inflammatory drugs (NSAIDs), to ease symptoms of acute respiratory infections.
In an observational study, researchers analysed claims from Taiwan's National Health Insurance Programme over a seven-year period (2005-2011), including data from nearly 10,000 patients who were hospitalised for a heart attack.
The goal was to study whether two potential cardiac risk factors - an acute respiratory infection, such as a cold or influenza, and NSAID use - have a combined, joint effect on heart attack risk.
Using the pain relievers during an acute respiratory infection was associated with a 3.4-fold increased risk for a heart attack, with 7.2 times greater risk when patients received the pain-relieving medication intravenously in the hospital, compared to times when patients had neither of the risk factors.
The heart attack risk when patients with an acute respiratory illness were not taking an NSAID was 2.7 times greater, while the risk was 1.5 times greater when individuals took the drugs and did not have an infection.
"Physicians should be aware that the use of NSAIDs during an acute respiratory infection might further increase the risk of a heart attack," said study author Cheng-Chung Fang, from National Taiwan University Hospital.
Patients seeking relief from cold and flu symptoms should consult with their doctor or a pharmacist before using NSAIDs, said Fang.
Another commonly used pain reliever, acetaminophen, which eases pain in a different way than NSAIDs do, may be a safer alternative, in terms of cardiac risk, for relief from cold and flu symptoms, although the drug was not evaluated in the study.
Additional research is needed to clarify the apparent combined effect on risk and how the effect might be managed.
The study was published in the Journal of Infectious Diseases.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
